 |
| Great New Interviews with ATTD NFRX and PSID |
|
 Yesterday's Top Performer |
Company: PositiveID Corporation (OTCBB: PSID)
|
End of Day:
Price: 0.0195
Change (%): + 0.001 (5.41)
Volume: 4,142,616 |
 |
In a New Audio Interview at SmallCapVoice.com, William J. Caragol, Chairman and CEO of PositiveID, Provides Details Regarding License and Teaming Agreement With The Boeing Company
AUSTIN, Texas, Jan. 3, 2013 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. announced today that a new audio interview with PositiveID Corporation (OTCBB:PSID), an emerging growth company and developer of airborne bio-threat detection systems for America's homeland defense industry as well as advanced technologies for rapid medical testing and diabetes management, is now available. The interview can be heard at http://smallcapvoice.com/blog/12-26-12-smallcapvoice-interview-with-positiveid-corporation-psid.
William J. Caragol, Chairman and CEO of PositiveID, stated, "By entering into this teaming agreement with such a world-class company, we believe we have positioned our unique M-BAND system to be an integral component of the upcoming 3.1 billion dollar BioWatch Gen-3 system procurement. We will also maintain our role as the exclusive provider of assays and reagents under the teaming agreement for this important homeland defense program."
Continue Reading
|
 Hot Stock to Watch
|
Company: Attitude Drinks, Inc. (OTCBB: ATTD)
|
End of Day:
Price: 0.0002
Change (%): + 0.00 (0.00)
Volume: 168,910,543 |
 |
A New Audio Interview With Roy Warren, CEO of Attitude Drinks, is Now at SmallCapVoice.com
AUSTIN, Texas, Jan. 3, 2013 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. announced today that a new audio interview with American Attitude Drinks (OTCBB:ATTD) (OTCQB:ATTD), an innovative brand beverage development company and creator of the Phase III® Recovery brand, is now available. The interview can be heard at http://smallcapvoice.com/blog/12-31-12-smallcapvoice-interview-with-attitude-drinks-incorporated-attd
"In my 35 year experience as an entrepreneur, I have learned that successful businesses are built upon products and services which embody solid fundamentals. Timing and integrity are critical in brand development; I believe 2013 is the year for Phase III Recovery to achieve broad-based consumer demand," stated Roy Warren, CEO of Attitude Drinks.
Continue Reading
|
Company: InferX Corporation (OTCBB: NFRX)
|
End of Day:
Price: 0.0509
Change (%): - 0.0011 (2.12)
Volume: 305,452 |
 |
A New Audio Interview With Paul B. Silverman, President and CEO of InferX Corporation, is Now at SmallCapVoice.com
AUSTIN, Texas, Jan. 3, 2013 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. announced today that a new audio interview with InferX Corporation (OTCBB:NFRX), a pioneer in advanced predictive analytics solutions in the rapidly growing analytics market addressing health care and other key market sectors, is now available. The interview can be heard at http://smallcapvoice.com/blog/12-31-12-smallcapvoice-interview-with-inferx-corp-nfrx
Paul B. Silverman, President and CEO of InferX called into SmallCapVoice.com to go over the business model, market, the recent news for company and much more. The interview also includes the goals in 2013.
Continue Reading |
Other Small Cap News
|
Company: TG Therapeutics, Inc. (OTCBB: TGTX)
|
TG Therapeutics, Inc. Announces FDA Clearance to Commence Clinical Trials of Its Novel, PI3K-Delta Specific Inhibitor, TGR-1202, Under Its Recently Filed U.S. Investigational New Drug (IND) Application
NEW YORK, Jan. 3, 2013 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX) today announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") Application for TGR-1202, the Company's novel, highly specific PI3K-Delta inhibitor being developed jointly with Rhizen Pharmaceuticals, S A.
"This is an exciting way to start the new year. TGR-1202 holds great promise and this is the first step to determining its true potential. We look forward to opening our first-in-human clinical trial as soon as possible," stated Michael S. Weiss, Executive Chairman and Interim CEO of TG Therapeutics, continuing, "The great speed at which the team moved to achieve this milestone for TGR-1202 is extremely impressive considering our global development agreement was just recently executed in the 3rd quarter of 2012. Our team is eager to continue this aggressive pace as we implement the clinical development program planned for TGR-1202."
Continue Reading
|
Company: Eco Building Products, Inc. (OTCBB: ECOB)
|
Eco Building Products Making Presence Known in Disaster Prone Colorado Housing Market
Saddletree Homes Embraces Eco Red Shield Protection for the Rebuilding Amongst the Wake of the Waldo Canyon Fire Storm
VISTA, Calif., Jan. 3, 2013 /PRNewswire/ -- Eco Building Products, Inc., (OTCBB: ECOB) announced today that the Company's flagship Eco Red Shield ™ lumber protection has found success in the fire storm disaster prone region of Colorado Springs. Saddletree Homes is being recognized as the first Colorado regional homebuilder to embrace our defensive building product, and is doing so on a house being rebuilt in the wake of the devastating 2012 Waldo Canyon fires. With construction scheduled to commence on January 28th, the home located on Linger Way in Colorado Springs, will boast Eco Red Shield protection, exemplifying a step in the right direction for the building industry armed with the latest in defensive building technology.
Continue Reading
|
Company: Xstelos Holdings, Inc. (OTCQB: XTLS)
|
Auxilium Pharmaceuticals, Inc. and Xstelos Holdings, Inc. Receive 505(b)(2) Paragraph IV Certification Notice from Upsher-Smith Laboratories, Inc. for Testim®
MALVERN, Pa. and NEW YORK, Jan. 3, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) ("Auxilium") and Xstelos Holdings, Inc. (OTCQB: XTLS) ("Xstelos") today announced that they have received a notice from Upsher-Smith Laboratories, Inc. ("USL") that advises them of USL's filing of a 505(b)(2) New Drug Application (NDA) containing a Paragraph IV certification under 21 U.S.C. Section 314.52(c) for testosterone gel. This Paragraph IV certification notice refers to the ten U.S. patents, covering Testim®, 1% testosterone gel, that are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), published by the U.S. Food and Drug Administration. These ten patents are owned by FCB I LLC, an indirect majority owned subsidiary of Xstelos. Xstelos holds the assets of CPEX Pharmaceuticals, Inc., the predecessor owner of the patents. The referenced Testim patents will expire between 2023 and 2025.
Continue Reading |
Market News
|
Associated Press
|
Futures off as Congress heads for another showdown
US stock futures declining as debt ceiling looms; automakers and retailers post monthly sales
NEW YORK (AP) -- U.S. stock futures slipped Thursday with some retailers posting lackluster sales for December and a new fight looming in Congress.
Unemployment benefit applications rose as well last week, but those numbers were likely distorted by the holidays.
Dow Jones industrial futures fell 22 points to 13,309. The broader S&P futures gave up 2.4 points to 1,454.70. Nasdaq futures slipped 3 points to 2,735.75.
Continue Reading
|
By Catherine Boyle: Staff Writer, CNBC.com
|
After 'Horrid' Cliff Deal, Buy Stocks: Dennis Gartman
The deal finally reached over the U.S. "fiscal cliff" should ultimately be positive for the U.S. stock market and investors should buy U.S. equities on any weakness next week, according to The Gartman Letter writer and editor Dennis Gartman.
"This was horrid, awful, vile legislation but we had to pass it and now we can put this fiscal cliff behind us for a while," Gartman told CNBC Thursday, as the rally in global stock markets which followed Wednesday's deal showed signs of fading.
Gartman pointed out that the New Year often starts with a rally because of increased inflows, and said that weakness in U.S. equities should be bought, while investors should sell off the debt markets on their relative strength.
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the "unsubscribe" link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
